MyMD-1 is under clinical development by MyMD Pharmaceuticals and currently in Phase I for Multiple Sclerosis. According to GlobalData, Phase I drugs for Multiple Sclerosis have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MyMD-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MyMD-1 overview

MyMD-1 (Isomyosamine) is under development for the treatment of multiple sclerosis, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, immune mediated depression in patients with post acute sequelae of COVID-19, sarcopenia, frailty, chronic inflammation, rheumatoid arthritis, type 2 diabetes, inflammatory bowel disease, delay aging, cytokine storm and traumatic optic neuropathy (TON). It is a synthetic derivative of tobacco alkaloids, that is administered through oral route as capsule and tablet.

MyMD Pharmaceuticals overview

MyMD Pharmaceuticals, Inc (MyMD), formerly, Akers Biosciences Inc is a medical device company that develops, manufactures and supplies point-of-care screening and testing products. The company provides clinical diagnostics, safety diagnostics, and wellness products. ABI products include BreathScan alcohol detectors, CHUBE, METRON, PIFA PLUSS PF4, tri-cholesterol, PIFA chlamydia, PIFA dengue fever, PIFA malaria, PIFA syphilis, PIFA heparin, and breath ketone. The company provides testing platform technologies, which include micro particle catalyzed biosensor, particle immune-filtration assay, rapid enzymatic assay, rapid blood cell separation, and synthetic macrocycle complex. The company serves medical clinicians, individuals, corporations, and law enforcement agencies, health professionals. MyMD is headquartered in West Deptford, New Jersey, the US.

For a complete picture of MyMD-1’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.